Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities law violations at Baxter International Inc. following serious safety concerns related to its Novum IQ Large Volume Pump, which has led to significant investor losses and stock price decline [2][3][5]. Group 1: Safety Concerns and Legal Investigation - A Missouri news outlet reported serious safety issues with Baxter's Novum IQ Large Volume Pump, citing a whistleblower who claimed the pumps were unsafe for patient treatment [3]. - Baxter acknowledged potential under infusion risks in warning letters to customers, disclosing one serious injury linked to the device [4]. - The FDA classified the situation as a Class I recall, indicating a severe risk of serious injury or death, with Baxter reporting 79 serious injury cases and two patient deaths associated with the device [4]. Group 2: Stock Price Impact - Following the announcement of a voluntary and temporary pause in shipments and installations of the Novum LVP, Baxter's stock price fell by $6.24 per share, or 22.4%, closing at $21.61 per share on July 31, 2025 [5].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Baxter International Inc. for misrepresentations regarding the safety of its Novum IQ Large Volume Pump, which allegedly concealed systemic issues that could endanger patients [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025 [1]. - The defendants are accused of misrepresenting the safety of the Novum IQ Large Volume Pump, which is used for intravenous fluid delivery, while hiding serious risks associated with the device [3]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by December 15, 2025, although participation as a class member does not require serving as a lead plaintiff [4]. - All legal representation in this case is on a contingency fee basis, meaning shareholders will not incur fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" and listed in The Legal 500 for sixteen consecutive years [5].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [1]. Group 1: Allegations and Issues - The lawsuit claims that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [1]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but failed to adequately address the issues through customer alerts [1]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 23, 2022, to July 30, 2025, and shareholders are encouraged to register for participation [2]. - The deadline for shareholders to seek lead plaintiff status is December 15, 2025, with no cost or obligation to participate in the case [2]. Group 3: Law Firm's Role - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased Baxter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Baxter International, Inc. (NYSE: BAX). Shareholders who purchased shares of BAX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/baxter-international-inc-loss-submission-form-2/?id=175415&from=3  CLASS PE ...

Business Transactions - The company completed the sale of its Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion, receiving approximately $3.71 billion in pre-tax cash proceeds at closing [167]. - The company completed the sale of its BioPharma Solutions business for cash proceeds of $3.96 billion, using the after-tax proceeds to repay debt obligations [172]. - The company repaid $3.81 billion of short- and long-term indebtedness during the first nine months of 2025, primarily from the sale of its Kidney Care business [258]. Financial Performance - The company reported a net loss attributable to stockholders of $(46) million, or $(0.09) per diluted share, for the three months ended September 30, 2025, compared to a net income of $140 million, or $0.27 per diluted share, for the same period in 2024 [181]. - For the nine months ended September 30, 2025, the company reported a net income of $171 million, or $0.33 per diluted share, compared to a net loss of $(137) million, or $(0.27) per diluted share, for the same period in 2024 [182]. - The company reported a net loss from continuing operations of $(51) million, or $(0.10) per diluted share, for the three months ended September 30, 2025 [183]. - Total net sales for the three months ended September 30, 2025, were $2,835 million, a 5% increase from $2,699 million in 2024 [186]. - Other revenues for the three months ended September 30, 2025, were $101 million, significantly up from $17 million in the prior year [205]. - Total reportable segment operating income was $433 million in Q3 2025, down from $462 million in Q3 2024 [236]. Segment Performance - In the third quarter of 2025, sales in the United States increased by 3% to $1,544 million, while emerging markets saw a 2% increase to $355 million [186]. - The Medical Products & Therapies segment reported net sales of $1,329 million, a 1% decrease compared to $1,342 million in the same period last year [190]. - Infusion Therapies & Technologies net sales decreased by 4% in the third quarter of 2025, primarily due to lower Novum LVP pump sales [192]. - Advanced Surgery segment net sales increased by 13% in the third quarter of 2025, driven by growth in hemostats and sealants [193]. - Healthcare Systems & Technologies segment net sales increased by 3% in the third quarter of 2025, reaching $773 million [197]. - Pharmaceuticals segment net sales increased by 7% in the third quarter of 2025, totaling $632 million [202]. - Drug Compounding net sales increased by 12% in the third quarter of 2025, driven by improved product mix and increased demand [204]. Expenses and Margins - Gross margin for Q3 2025 was $950 million, representing 33.5% of net sales, down from $1,033 million (38.3%) in Q3 2024, a decrease of 8.0% [209]. - SG&A expenses for Q3 2025 were $708 million, or 25.0% of net sales, compared to $754 million (27.9%) in Q3 2024, a reduction of 6.1% [209]. - R&D expenses for Q3 2025 totaled $118 million, accounting for 4.2% of net sales, down from $129 million (4.8%) in Q3 2024, an 8.5% decrease [209]. - For the nine months ended September 30, 2025, gross margin was $2,802 million (33.9%), down from $3,025 million (38.4%) in the same period of 2024, a decline of 7.4% [210]. - SG&A expenses for the nine months ended September 30, 2025, were $2,129 million (25.7%), compared to $2,206 million (28.0%) in 2024, a decrease of 3.5% [210]. - R&D expenses for the nine months ended September 30, 2025, were $392 million (4.7%), slightly up from $379 million (4.8%) in 2024, an increase of 3.4% [210]. Special Items and Adjustments - The company incurred special items that adversely impacted net income by $401 million, or $0.78 per diluted share, for the three months ended September 30, 2025 [181]. - Special items negatively impacted the gross margin ratio by approximately 5.9 percentage points in Q3 2025 and 6.7 percentage points for the nine months ended September 30, 2025 [211]. - Business optimization charges for Q3 2025 amounted to $38 million, compared to $18 million in Q3 2024, reflecting restructuring efforts post-sale of the Kidney Care segment [212]. - The company expects to incur additional pre-tax costs of approximately $1 million related to ongoing business optimization initiatives [220]. Cash Flow and Debt - Cash flows from operations for the nine months ended September 30, 2025 were $355 million, down from $376 million in the same period of 2024, affected by increased inventory levels [246]. - Cash used in financing activities for the nine months ended September 30, 2025 included debt repayments of $3.51 billion, compared to $827 million in the same period of 2024 [248]. - As of September 30, 2025, the company had $1.73 billion of cash and cash equivalents available to meet operating requirements [258]. - The company had $645 million outstanding under its U.S. Dollar-denominated term loan credit facility, which matures in 2027 [252]. - The Multicurrency Revolver has a maximum capacity of $2.20 billion and matures in 2030, with no borrowings outstanding as of September 30, 2025 [253]. Risks and Challenges - The company experienced challenges in its global supply chain due to Hurricane Helene, which disrupted operations at its North Cove facility [173]. - The company faced adverse impacts from global macroeconomic conditions, including high inflation rates, which have affected costs and customer order patterns [177]. - The company is exposed to foreign exchange risk with revenues generated outside the U.S. in multiple currencies, including Euro, British Pound, and Japanese Yen [273]. - The company faces risks related to the continuity and pricing of acceptable raw materials and component parts, impacting manufacturing and distribution [271]. - The company is subject to various risks including demand and market acceptance for new and existing products, competitive pressures, and challenges in predicting customer preferences [270]. Strategic Initiatives - The company has undertaken strategic actions, including the sale of its Kidney Care business and the acquisition of Hillrom, to achieve long-term financial improvement goals [270]. - The company is focused on developing and integrating artificial intelligence and other emerging technologies into its products and services [271]. Tax and Credit Ratings - Effective income tax rate was 142% for Q3 2025 compared to 12% for Q3 2024, influenced by an increase in liabilities for uncertain tax positions [224]. - Moody's revised the company's senior debt credit rating outlook from stable to negative during the third quarter of 2025 [260].

Core Viewpoint - Investors in Baxter International, Inc. have the opportunity to lead a securities fraud class action lawsuit due to undisclosed systemic defects in the Novum LVP device that resulted in serious patient risks [2]. Summary by Sections Lawsuit Details - The lawsuit alleges that from February 23, 2022, to July 30, 2025, Baxter failed to disclose significant issues with the Novum LVP, including systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not adequately address them, leading to misleading positive statements about the company's operations and prospects [2]. Participation Information - Investors who suffered losses related to Baxter are encouraged to participate in the ongoing lawsuit, with a lead plaintiff deadline set for December 15, 2025 [2]. - Interested parties can contact The Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of federal securities law violations related to the Novum LVP device, which reportedly suffered systemic defects leading to serious patient risks [4][6]. Group 1: Allegations Against Baxter - The complaint alleges that Baxter and its executives made false or misleading statements regarding the Novum LVP, failing to disclose systemic defects that caused malfunctions, including underinfusion and overinfusion, which posed risks of serious injury or death to patients [6]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to continued harm to patients [6]. - The company’s statements about the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading based on the undisclosed risks and defects [6]. Group 2: Impact on Stock and Legal Proceedings - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, which resulted in a 22.4% drop in stock price, closing at $21.76 [7]. - Investors who suffered losses exceeding $10,000 between February 23, 2022, and July 30, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights, with a deadline of December 15, 2025, to seek the role of lead plaintiff in the class action [4][9].

Core Viewpoint - Baxter International (BAX) was regarded as a strong player in the healthcare sector before the pandemic, with its stock trading at approximately 25 times the earnings per share at the end of 2019, indicating a significant premium valuation [1]. Group 1 - The stock performance of Baxter International prior to the pandemic was notable, reflecting investor confidence in its business model and growth potential [1].

Before the pandemic, Baxter International ( BAX ) was considered one of the better businesses in the health care space. At the end of 2019, BAX stock traded at about 25x that year's earnings per share, a significant premiumI've been contributing to Seeking Alpha and other investment websites since 2011, with a general (though far from rigid) focus on value over growth. I got my Series 7 and 63 back in 1999, and watched the dot-com bubble peak and then burst in real time at a small, tech-focused retail broke ...